Welcome to our dedicated page for Paragon 28 news (Ticker: FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.
Overview of Paragon 28 Inc
Paragon 28 Inc (FNA) is a specialized medical device company dedicated exclusively to the foot and ankle orthopedic segment. Established in 2010 with a clear mission to blend surgical innovation and quality, the company has built a comprehensive portfolio of surgical solutions targeting complex foot and ankle procedures. Utilizing advanced technologies in orthopedic implants and surgical instrumentation, Paragon 28 aims to set a benchmark in innovation and operational efficiency within the medical device industry.
Mission and Core Values
From its humble beginnings as a small, family-based business, Paragon 28 has consistently maintained its core ideals of innovation, quality, and dedicated service. The company's name is a tribute to its exclusive focus on foot and ankle surgery, with the number '28' symbolizing the anatomical complexity of the human foot. Central to its mission is the drive to advance the science of foot and ankle surgery by integrating diverse surgical philosophies from global thought leaders, ensuring that each surgical solution meets stringent biomechanical and clinical standards.
Comprehensive Product Portfolio
Paragon 28 offers an extensive suite of nearly 80 proprietary surgical product systems. These include a range of orthopedic devices such as plates, plating systems, screws, staples, and nails. These products are meticulously designed to address a variety of foot and ankle procedures including:
- Ankle reconstruction and fixation for complex fractures and musculoskeletal trauma
- Fracture fixation solutions that ensure stability and promote healing
- Procedural instrumentation for deformity corrections, hallux valgus, hammertoe, and flatfoot conditions
- Innovative solutions for specialized conditions such as Charcot foot and progressive collapsing foot deformity
Operational Excellence and Distribution
The company leverages a dedicated and highly trained sales and distribution network to ensure that its advanced orthopedic devices reach a wide network of surgical centers and hospitals, primarily within the United States. This customer-centric approach, combined with efficient operational practices, allows Paragon 28 to address the dual challenges of increasing pricing pressures and reimbursement complexities within the healthcare sector.
Competitive Position and Industry Impact
Operating within the dynamic and competitive landscape of orthopedics, Paragon 28 has distinguished itself through its unwavering focus on the foot and ankle segment. By prioritizing innovation and tailoring its product offerings to meet the precise needs of both patients and surgeons, the company has established a strong operational niche. Its strategy of blending global surgical insights with a rigorous quality framework enables it to create products that are not only clinically relevant but also easily reproducible in diverse surgical settings. This distinctive positioning highlights the company’s commitment to improving patient outcomes while maintaining operational efficiency.
Strategy and Business Model
Paragon 28's business model is anchored in its commitment to three primary pillars:
- Creation and Innovation: Investing in research and development to refine surgical techniques and develop devices that address specific clinical challenges in the foot and ankle spectrum.
- Focused Service: Establishing a robust distribution network that ensures timely delivery and superior customer service, which is critical for high-stakes surgical environments.
- Efficient Practices: Implementing operational efficiencies to navigate challenges related to evolving reimbursement frameworks and pricing pressures, thereby sustaining a cycle of quality and innovation.
Expertise and Authoritativeness
The company's process of integrating varied surgical philosophies into its product design reflects deep industry expertise. Paragon 28’s commitment to ongoing research and development, along with its emphasis on user-friendly yet technologically advanced products, positions it as a trusted name among orthopedic surgeons. The company’s continuous efforts in refining its product systems set a high standard of care in the specialized field of foot and ankle surgery.
Understanding the Technology and Innovation
In the realm of medical devices, technological innovation is crucial. Paragon 28 harnesses cutting-edge manufacturing techniques and research-driven insights to build devices that enhance surgical precision and reliability. This detailed approach ensures that each product not only conforms to current clinical requirements but also anticipates the nuanced challenges surgeons face during delicate procedures. The application of advanced orthopedic implant technologies and state-of-the-art design principles underscores the company’s commitment to facilitating optimal patient outcomes.
Market Significance and Industry Relevance
Although Paragon 28 operates within a specialized niche of the orthopedic implant market, the company’s influence is profound due to its unwavering focus on quality, innovation, and customer service. Its strategic approach, combined with a suite of versatile surgical solutions, effectively addresses critical gaps in the foot and ankle surgical procedural space. This specialization allows the company to serve a targeted customer base that includes orthopedic surgeons, hospitals, and outpatient surgical centers, all of which rely on dependable and innovative surgical solutions to improve patient care.
Conclusion
In summary, Paragon 28 Inc stands as a comprehensive, innovation-driven entity in the orthopedic medical device arena. Its focused mission, extensive product portfolio, and commitment to blending global surgical insights with efficient, reliable service have positioned it as a pivotal player in addressing the challenges of foot and ankle surgery. Through its attention to detail in both product development and operational execution, Paragon 28 offers a detailed case study of how concentrated expertise can drive significant advancements in medical technology.
Paragon 28, Inc. (NYSE: FNA) has launched the R3ACT™ Stabilization System, aimed at enhancing soft tissue healing for syndesmotic ankle injuries. This system is designed to address the complexities of stabilization throughout various healing phases. CEO Albert DaCosta emphasized that around 20% of ankle injuries necessitate implants for recovery, positioning the R3ACT™ as a valuable addition to their ankle fracture solutions. Paragon 28 specializes in the foot and ankle orthopedic market, focusing on innovative solutions to improve patient outcomes.
Paragon 28, Inc. (NYSE: FNA) announced it will release its Q1 2022 financial results after market close on May 9, 2022. A conference call will follow at 4:30 p.m. ET, and investors can access it by calling (844-200-6205) within the U.S. or (646-904-5544) internationally, using conference ID: 990038. CEO Albert DaCosta and CFO Steve Deitsch will also present at the Bank of America Healthcare Conference in Las Vegas on May 10, at 2:00 p.m. PT. Live webcasts will be available on the company’s website.
Paragon 28, Inc. (NYSE: FNA) has appointed Meghan Scanlon to its Board of Directors, enhancing its leadership team. With over 20 years in the medical device sector, Scanlon currently serves as senior vice president at Boston Scientific Corporation. She will also contribute to the Compensation and Quality, Technology and Regulatory Committees. Paragon 28 aims to improve outcomes for foot and ankle patients, focusing on innovative orthopedic solutions and procedural approaches.
Paragon 28, Inc. (NYSE: FNA), a premier medical device company focusing on foot and ankle orthopedics, announced presentations by CEO Albert DaCosta and CFO Steve Deitsch at the Canaccord Genuity Musculoskeletal Conference on March 22, 2022, and the Needham Healthcare Conference on April 11, 2022. Both events will be webcast live, with the Canaccord chat at 12:30pm ET and the Needham chat at 11:00am ET. Archived recordings will be available on the company’s investor relations website.
Paragon 28 (NYSE: FNA) reported Q4 2021 net revenue of $42.8 million, a 22% increase year-over-year, and total revenue of $147.5 million for 2021, reflecting 33% growth. The gross margin improved to 81.7% from 72.3% in the prior year, attributed to higher margin product sales. However, operating expenses surged to $40.0 million, leading to a net loss of $6.2 million. The company expects net revenue for 2022 to be between $167.0 million and $171.0 million, indicating growth of 13% to 16%, despite potential COVID-19 challenges.
Paragon 28, Inc. (NYSE: FNA), a medical device leader in the foot and ankle orthopedic market, will announce its Q4 and full year 2021 financial results on March 8, 2022, after market close. A conference call will follow at 4:30 p.m. ET, accessible via phone or through a webcast on the company’s website. Investors can dial (844-200-6205) domestically or (929-526-1599) internationally using conference ID: 902702. The audio will be archived for 90 days post-event.
Paragon 28, Inc. (NYSE: FNA) has announced the acquisition of Disior Oy, a software company specializing in 3D analytics for foot and ankle surgery. The $18 million upfront payment, with potential future payments of up to $8 million, aims to enhance Paragon 28's SMART 28™ ecosystem. This integration will improve pre-operative planning and surgical outcomes for foot and ankle surgeons, aligning with Paragon 28's mission to modernize surgery and enhance patient care.
Paragon 28, Inc. (NYSE: FNA) announced its preliminary unaudited revenue for Q4 and the full year ended December 31, 2021. Q4 revenue is projected between $42.3 million and $42.7 million, marking a growth of approximately 20.7% to 21.8% year-over-year. For the entire year, expected revenue is between $147.0 million and $147.4 million, reflecting a growth of 32.4% to 32.8% compared to 2020. The company attributes this growth to its innovative foot and ankle portfolio and recent IPO, which has strengthened its financial position.
Paragon 28, Inc. (NYSE: FNA) announced FDA 501(k) marketing clearance for its R3ACT™ Stabilization System, set for commercial launch in early 2022. This product enhances Paragon 28's existing portfolio aimed at ankle fractures and soft tissue stabilization. CEO Albert DaCosta highlighted the product's innovative design, which meets complex needs in syndesmotic stabilization and adapts to healing phases of soft tissues. This new addition complements current offerings, including the Gorilla® and Mini-Monster® systems, strengthening the company's position in the orthopedic market.
Paragon 28, Inc. (NYSE: FNA), a key player in the foot and ankle orthopedic market, announced a virtual presentation at the 24th Annual Needham Growth Conference on January 10, 2022. The event, featuring Chairman and CEO Albert DaCosta and CFO Steve Deitsch, will be webcast live at 2:45 PM ET. The presentation aims to showcase the company's commitment to innovative orthopedic solutions addressing various foot and ankle conditions. Investors can access the webcast and archived recording on the company's investor relations website.
FAQ
What is the current stock price of Paragon 28 (FNA)?
What is the market cap of Paragon 28 (FNA)?
What does Paragon 28 Inc specialize in?
What types of products does Paragon 28 offer?
How does Paragon 28 generate revenue?
What are the core values of Paragon 28 Inc?
How does Paragon 28 maintain industry expertise?
What distinguishes Paragon 28 in the competitive orthopedic market?
Who are the primary customers of Paragon 28?
How does Paragon 28 address the challenges in the healthcare market?
